The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
OPERETTA: A phase II study evaluating neoadjuvant and adjuvant olaparib plus pembrolizumab following platinum-based chemotherapy plus pembrolizumab for germline BRCA mutated triple negative breast cancer.
 
Yuko Takahashi
Research Funding - MSD (Inst)
 
Kumiko Kida
No Relationships to Disclose
 
Meiko Nishimura
No Relationships to Disclose
 
Kaori Terata
Speakers' Bureau - AstraZeneca; Chugai Pharma; Daiichikyo; Pfizer
 
Manabu Futamura
No Relationships to Disclose
 
Atsushi Yoshida
No Relationships to Disclose
 
Tadahiko Shien
Consulting or Advisory Role - Allergan; AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Kirin; Lilly; Novartis; Pfizer; Taiho Pharmaceutical; Takeda
Speakers' Bureau - Allergan; AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Kirin; Lilly; Nihonkayaku; Novartis; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Eisai (Inst); Nihonkayaku (Inst)
 
Takayuki Ueno
Honoraria - AstraZeneca Japan; Chugai Pharma; Eisai; Novartis
Research Funding - Lilly Japan (Inst)
 
Toshimi Takano
Honoraria - Daiichi Sankyo; Lilly